← Back to home

Part 2: HER2 expressing/amplified solid tumors excluding breast, gastric, colorectal cancer

Clinical trials for Part 2: HER2 expressing/amplified solid tumors excluding breast, gastric, colorectal cancer explained in plain language.

Never miss a new study

Get alerted when new Part 2: HER2 expressing/amplified solid tumors excluding breast, gastric, colorectal cancer trials appear

Sign up with your email to follow new studies for Part 2: HER2 expressing/amplified solid tumors excluding breast, gastric, colorectal cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug shows promise against multiple Hard-to-Treat cancers

Disease control Ongoing

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

Matched conditions: PART 2: HER2 EXPRESSING/AMPLIFIED SOLID TUMORS EXCLUDING BREAST, GASTRIC, COLORECTAL CANCER

Phase 2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jul 12, 2026 00:00 UTC

Part 2: HER2 expressing/amplified solid tumors excluding breast, gastric, colorectal cancer

Get alerted when new Part 2: HER2 expressing/amplified solid tumors excluding breast, gastric, colorectal cancer trials appear

New drug shows promise against multiple Hard-to-Treat cancers